Skip to main content

Panacea Biotec receives UNICEF & PAHO awards for supply of Pentavalent Vaccine (DTwP-HepB-Hib)

New Delhi, India, October 9, 2022 – Panacea Biotec, one of India’s leading biotechnology companies, has received long-term supply awards worth US$ 127.30 million (around INR 1,040 Crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT® (DTwP-HepB-Hib).

UNICEF award is worth US$ 98.755 million ( INR 813 Crore) for supply of 99.70 million doses during calendar years 2023-2027 and PAHO award is worth US$ 28.55 million ( INR 235 Crore) for supply 24.83 million doses during calendar years 2023-2025.

Read the full press release here